Review
Biochemistry & Molecular Biology
Stephen D. H. Malnick, Pavel Alin, Marina Somin, Manuela G. Neuman
Summary: Both alcohol-induced liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) involve abnormal fat accumulation in the liver, potentially caused by excessive alcohol consumption and the combination of alcohol consumption and medications. The liver pathology is similar in both conditions, progressing from simple steatosis to inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Evaluating the medical history of alcohol consumption, laboratory markers, AST/ALT ratio, and features of the metabolic syndrome can help estimate the contribution of alcohol intake and metabolic syndrome to liver steatosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Food Science & Technology
Keisuke Hamada, Ping Wang, Yangliu Xia, Nana Yan, Shogo Takahashi, Kristopher W. Krausz, Haiping Hao, Tingting Yan, Frank J. Gonzalez
Summary: WA has therapeutic effects on alcoholic liver disease by inhibiting hepatic lipogenesis to reduce liver injury caused by alcohol.
FOOD AND CHEMICAL TOXICOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Ji Ye Hyun, Seul Ki Kim, Sang Jun Yoon, Su Been Lee, Jin-Ju Jeong, Haripriya Gupta, Satya Priya Sharma, Ki Kwong Oh, Sung-Min Won, Goo Hyun Kwon, Min Gi Cha, Dong Joon Kim, Raja Ganesan, Ki Tae Suk
Summary: Alcohol consumption leads to various liver diseases, and gut microbiome plays a significant role in the development of these diseases. It causes intestinal permeability, metabolic disorder, oxidative stress, liver inflammation, and hepatocellular injury. Future research can focus on genetic, microbial, and metabolic regulation in alcoholic liver diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Yoon Mee Yang, Ye Eun Cho, Seonghwan Hwang
Summary: Alcoholic liver disease (ALD), caused by excessive alcohol consumption, results in liver damage. Studies have shown that there is a relationship between hepatic oxidative stress and inflammatory responses, which may be useful for developing therapeutic approaches for ALD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Fei Yuan, Jun-nan Cai, Meng Dai, Xiongwen Lv
Summary: In this study, the role of P2Y6 in alcoholic steatohepatitis was investigated. P2Y6 levels were found to be elevated in Kupffer cells in mice with alcoholic steatohepatitis and ethanol-induced RAW264.7 cells. Inhibition of P2Y6 showed improvement in steatosis and inflammation, while P2Y6 activation had contrasting results. Furthermore, P2Y6 was found to regulate the activation of the p38 MAPK signaling pathway through mediating calcium influx. Targeting P2Y6 signaling may be a potentially effective strategy for the treatment of alcoholic steatohepatitis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Nutrition & Dietetics
Ludovico Abenavoli, Tiziana Larussa, Alessandro Corea, Anna Caterina Procopio, Luigi Boccuto, Marcello Dallio, Alessandro Federico, Francesco Luzza
Summary: NAFLD, characterized by a wide spectrum of liver disorders, is considered a major public health issue globally. Polyphenols, known for their anti-inflammatory and antioxidant properties, are believed to have potential benefits in preventing and treating NAFLD, though limited human clinical trials are available.
Review
Medicine, General & Internal
Elizabeth E. Powell, Vincent Wai-Sun Wong, Mary Rinella
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common global health issue with significant associations with metabolic syndrome and type 2 diabetes, leading to serious complications like cirrhosis and hepatocellular carcinoma. While cardiovascular disease and extrahepatic malignancy are the main causes of death in NAFLD patients, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality.
Article
Cell Biology
Junliang Kuang, Jieyi Wang, Yitao Li, Mengci Li, Mingliang Zhao, Kun Ge, Dan Zheng, Kenneth C. P. Cheung, Boya Liao, Shouli Wang, Tianlu Chen, Yinan Zhang, Congrong Wang, Guang Ji, Peng Chen, Hongwei Zhou, Cen Xie, Aihua Zhao, Weiping Jia, Xiaojiao Zheng, Wei Jia
Summary: A new treatment for alleviating NAFLD has been discovered, which involves inhibiting intestinal FXR and upregulating hepatic CYP7B1 through a group of gut microbiota-modified bile acids. These bile acids can also increase the abundance of probiotic species and enhance lipid catabolism through the activation of PPARα signaling pathway, leading to an upregulation of hepatic FXR.
Article
Medicine, Research & Experimental
Tatsunori Miyata, Xiaoqin Wu, Xiude Fan, Emily Huang, Carlos Sanz-Garcia, Christina K. Cajigas-Du Ross, Sanjoy Roychowdhury, Annette Bellar, Megan R. McMullen, Jaividhya Dasarathy, Daniela S. Allende, Joan Caballeria, Pau Sancho-Bru, Craig J. McClain, Mack Mitchell, Arthur J. McCullough, Svetlana Radaeva, Bruce Barton, Gyongyi Szabo, Srinivasan Dasarathy, Laura E. Nagy
Summary: The study found that MLKL plays a different role in ALD and NAFL/NASH mouse models, and suggested that RIP1-RIP3-MLKL can be used as biomarkers to distinguish alcohol-associated hepatitis (AH) from NASH.
Review
Biochemistry & Molecular Biology
Carlos Jimenez-Cortegana, Alba Garcia-Galey, Malika Tami, Pilar del Pino, Isabel Carmona, Soledad Lopez, Gonzalo Alba, Victor Sanchez-Margalet
Summary: NAFLD affects a quarter of the global population and poses a significant health and economic burden across all countries. The lack of approved pharmacotherapy and well-established diagnostic strategies for this disease highlights the urgency for further research and management efforts. Studies have shown a strong relationship between the hormone leptin and the development of NAFLD, suggesting potential advancements in disease management through further investigation of its role.
Review
Endocrinology & Metabolism
Herbert Tilg, Timon E. Adolph, Michael Dudek, Percy Knolle
Summary: Non-alcoholic fatty liver disease (NAFLD) is a global pandemic that particularly affects patients with obesity and type 2 diabetes. The complex interplay between metabolic dysregulation, altered gut microbiome and dysregulated innate and adaptive immunity contributes to the pathology and progression of NAFLD.
Review
Cell Biology
Daryl Ramai, Antonio Facciorusso, Erika Vigandt, Bryan Schaf, Waleed Saadedeen, Aditya Chauhan, Sara di Nunzio, Aashni Shah, Luca Giacomelli, Rodolfo Sacco
Summary: NASH is a chronic and progressive form of non-alcoholic fatty liver disease with increasing global incidence, posing an epidemic and public health threat. The disease is associated with major morbidity and mortality, with patients at risk of developing hepatocellular carcinoma. Current evidence suggests a multi-hit model involving various pathways leading to progressive fibrosis and oncogenesis, highlighting the complexity of the disease.
Article
Multidisciplinary Sciences
Roberta D'Ambrosio, Irene Campi, Marco Maggioni, Riccardo Perbellini, Enza Giammona, Roberta Stucchi, Marta Borghi, Elisabetta Degasperi, Annalisa De Silvestri, Luca Persani, Laura Fugazzola, Pietro Lampertico
Summary: Hypothyroidism is common in NAFLD patients and is associated with increased NAFLD activity, but not with the severity of fibrosis and steatosis. Thyroid dysfunction may play a role in the pathogenesis of NAFLD and NASH.
Article
Multidisciplinary Sciences
Minxuan Xu, Jun Tan, Wei Dong, Benkui Zou, Xuepeng Teng, Liancai Zhu, Chenxu Ge, Xianling Dai, Qin Kuang, Shaoyu Zhong, Lili Lai, Chao Yi, Tingting Tang, Junjie Zhao, Longyan Wang, Jin Liu, Hao Wei, Yan Sun, Qiufeng Yang, Qiang Li, Deshuai Lou, Linfeng Hu, Xi Liu, Gang Kuang, Jing Luo, Mingxin Xiong, Jing Feng, Chufeng Zhang, Bochu Wang
Summary: This study reveals that Trim31 acts as an endogenous inhibitor of Rhbdf2 in mice, mitigating the development of NASH and potentially serving as a therapeutic target for treating NAFLD/NASH and associated metabolic disorders.
NATURE COMMUNICATIONS
(2022)
Review
Gastroenterology & Hepatology
Rajiv Heda, Masahiko Yazawa, Michelle Shi, Madhu Bhaskaran, Fuad Zain Aloor, Paul J. Thuluvath, Sanjaya K. Satapathy
Summary: The increasing prevalence of obesity and diabetes in the United States and globally is expected to lead to a rise in the overall incidence and prevalence of non-alcoholic fatty liver disease (NAFLD). Risk factors for NAFLD are also linked to the development of chronic kidney disease (CKD). Potential therapeutic implications for this patient population include mechanisms like ectopic lipid accumulation and cellular signaling abnormalities. Strategies for surveillance and management involve monitoring comorbidities, using non-invasive fibrosis scoring systems, and measuring laboratory markers. Treatment approaches range from preventative measures to experimental interventions for patients with NAFLD and CKD.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)